4 Analysts Have This to Say About Beam Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, Beam Therapeutics (NASDAQ:BEAM) received mixed ratings from four analysts. The average price target is $48.5, which is significantly higher than the current price of $23.8. This average represents a 1.02% decrease from the previous average price target of $49.00.
August 29, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Beam Therapeutics received mixed ratings from analysts, with an average price target of $48.5, higher than its current price.
The average price target given by analysts is significantly higher than the current price of Beam Therapeutics, indicating a potential upside. However, the ratings are mixed, which may create uncertainty among investors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100